Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.

Leone, Gian Marco; Candido, Saverio; Lavoro, Alessandro; Vivarelli, Silvia; Gattuso, Giuseppe; Calina, Daniela; Libra, Massimo; Falzone, Luca

Leone, Gian Marco; Candido, Saverio; Lavoro, Alessandro; Vivarelli, Silvia; Gattuso, Giuseppe; Calina, Daniela; Libra, Massimo; Falzone, Luca.

Afiliación

Leone GM; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Candido S; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Lavoro A; Research Center for Prevention, Diagnosis and Treatment of Cancer, University of Catania, 95123 Catania, Italy.
Vivarelli S; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Gattuso G; Department of Biomedical and Dental Sciences, Morphological and Functional Imaging, Section of Occupational Medicine, University of Messina, 98125 Messina, Italy.
Calina D; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Libra M; Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Falzone L; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Pharmaceutics ; 15(4)2023 Apr 16.

Article en En | MEDLINE | ID: mdl-37111737

Palabras clave

dysbiosis; immune-checkpoint inhibitors; lung cancer; microbiome; targeted therapy; tyrosine kinase inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google